{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:31:19Z","timestamp":1793766679110,"version":"4.6.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VA National Center for PTSD"},{"name":"Fulbright Award"},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"N\/A"},{"name":"Transcend Therapeutics"},{"name":"Transcend Therapeutics; Freedom Biosciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41380-026-03713-1","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:52:42Z","timestamp":1783403562000},"page":"6433-6444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u03b12-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice"],"prefix":"10.1038","volume":"31","author":[{"given":"Axel F.","family":"Rosado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2194-5028","authenticated-orcid":false,"given":"Abigail L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1220-4312","authenticated-orcid":false,"given":"Jen-Hau","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Staszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-361X","authenticated-orcid":false,"given":"Mark","family":"Dibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Warner-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelmendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-1726","authenticated-orcid":false,"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2117-9321","authenticated-orcid":false,"given":"Christopher","family":"Pittenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-1667","authenticated-orcid":false,"given":"Alex C.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-1221","authenticated-orcid":false,"given":"Alfred P.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"3713_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/7854_2017_478","volume":"36","author":"JF L\u00f3pez-Gim\u00e9nez","year":"2018","unstructured":"L\u00f3pez-Gim\u00e9nez JF, Gonz\u00e1lez-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45\u201373. https:\/\/link.springer.com\/chapter\/10.1007\/7854_2017_478","journal-title":"Curr Top Behav Neurosci"},{"key":"3713_CR2","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328\u201334. https:\/\/www.nature.com\/articles\/s41386-019-0360-5","journal-title":"Neuropsychopharmacology"},{"key":"3713_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61:364\u201381. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.017","journal-title":"Neuropharmacology"},{"key":"3713_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439\u201352. https:\/\/doi.org\/10.1016\/j.neuron.2007.01.008","journal-title":"Neuron"},{"key":"3713_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03421-4","volume":"15","author":"I Erkizia-Santamar\u00eda","year":"2025","unstructured":"Erkizia-Santamar\u00eda I, Horrillo I, Mart\u00ednez-\u00c1lvarez N, P\u00e9rez-Mart\u00ednez D, Rivero G, Erdozain AM, et al. Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress. Transl Psychiatry. 2025;15:201 https:\/\/doi.org\/10.1038\/s41398-025-03421-4","journal-title":"Transl Psychiatry"},{"key":"3713_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111243","volume":"136","author":"Z Wang","year":"2025","unstructured":"Wang Z, Robbins B, Zhuang R, Sandini T, van Bruggen R, Li XM, et al. Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111243 https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111243","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3713_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41386-024-01794-6","volume":"49","author":"M Sekssaoui","year":"2024","unstructured":"Sekssaoui M, Bockaert J, Marin P, B\u00e9camel C. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? Neuropsychopharmacology. 2024;49:747\u201356. https:\/\/doi.org\/10.1038\/s41386-024-01794-6","journal-title":"Neuropsychopharmacology"},{"key":"3713_CR8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41593-025-02068-0","volume":"28","author":"A Hammo","year":"2025","unstructured":"Hammo A, Wisser S, Cichon J. Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain. Nat Neurosci. 2025;28:2285\u201395. https:\/\/doi.org\/10.1038\/s41593-025-02068-0","journal-title":"Nat Neurosci"},{"key":"3713_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 1986;18:305\u201313. https:\/\/doi.org\/10.1080\/02791072.1986.10472362","journal-title":"J Psychoactive Drugs"},{"key":"3713_CR10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/npp.2011.304","volume":"37","author":"MH Baumann","year":"2012","unstructured":"Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;37:1192\u2013203. https:\/\/doi.org\/10.1038\/npp.2011.304","journal-title":"Neuropsychopharmacology"},{"key":"3713_CR11","doi-asserted-by":"publisher","unstructured":"Halberstadt AL Pharmacology and toxicology of N-benzylphenethylamine (\u201cNBOMe\u201d) hallucinogens. In: Neuropharmacology of New Psychoactive Substances (NPS). 2017. p. 283\u2013311. https:\/\/doi.org\/10.1007\/7854_2016_64","DOI":"10.1007\/7854_2016_64"},{"key":"3713_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1122861","volume":"14","author":"L Poyatos","year":"2023","unstructured":"Poyatos L, P\u00e9rez-Ma\u00f1\u00e1 C, Hladun O, N\u00fa\u00f1ez-Montero M, de la Rosa G, Mart\u00edn S, et al. Pharmacological effects of methylone and MDMA in humans. Front Pharmacol. 2023;14:1122861 https:\/\/doi.org\/10.3389\/fphar.2023.1122861","journal-title":"Front Pharmacol"},{"key":"3713_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2021.780500","volume":"15","author":"S Khom","year":"2021","unstructured":"Khom S, Nguyen JD, Vandewater SA, Grant Y, Roberto M, Taffe MA. Self-administration of entactogen psychostimulants dysregulates GABA and kappa opioid receptor signaling in the central nucleus of the amygdala of female Wistar rats. Front Behav Neurosci. 2021;15:780500. https:\/\/doi.org\/10.3389\/fnbeh.2021.780500","journal-title":"Front Behav Neurosci"},{"key":"3713_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/157015911795017254","volume":"9","author":"Y Hagino","year":"2011","unstructured":"Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, Murphy DL, Uhl GR, et al. Effects of MDMA on extracellular dopamine and serotonin levels in mice lacking dopamine and\/or serotonin transporters. Curr Neuropharmacol. 2011;9:91\u20135. https:\/\/doi.org\/10.2174\/157015911795017254","journal-title":"Curr Neuropharmacol"},{"key":"3713_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ejphar.2003.08.077","volume":"43","author":"AE Fleckenstein","year":"2003","unstructured":"Fleckenstein AE, Volz TJ, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter-2 function. Neurochem Int. 2003;43:329\u201338. https:\/\/doi.org\/10.1016\/j.ejphar.2003.08.077","journal-title":"Neurochem Int"},{"key":"3713_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1085\/jgp.201711980","volume":"150","author":"D Yaffe","year":"2018","unstructured":"Yaffe D, Forrest LR, Schuldiner S. The ins and outs of vesicular monoamine transporters. J Gen Physiol. 2018;150:671\u2013682. https:\/\/doi.org\/10.1085\/jgp.201711980","journal-title":"J Gen Physiol"},{"key":"3713_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1749-6632.2010.05906.x","volume":"1221","author":"LE Eiden","year":"2011","unstructured":"Eiden LE, Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann NY Acad Sci. 2011;1221:67\u201376. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05906.x","journal-title":"Ann NY Acad Sci"},{"key":"3713_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.863088","volume":"13","author":"DE Nichols","year":"2022","unstructured":"Nichols DE. Entactogens: how the name for a novel class of psychoactive agents originated. Front Psychiatry. 2022;13:863088 https:\/\/doi.org\/10.3389\/fpsyt.2022.863088.","journal-title":"Front Psychiatry"},{"key":"3713_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","volume":"94","author":"D Luethi","year":"2020","unstructured":"Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020;94:1085\u20131133. https:\/\/doi.org\/10.1007\/s00204-020-02693-7","journal-title":"Arch Toxicol"},{"key":"3713_CR20","doi-asserted-by":"publisher","first-page":"14148","DOI":"10.3390\/ijms232214148","volume":"23","author":"O Shahar","year":"2022","unstructured":"Shahar O, Botvinnik A, Esh-Zuntz N, Brownstien M, Wolf R, Lotan A, et al. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: translational implications. Int J Mol Sci. 2022;23:14148. https:\/\/doi.org\/10.3390\/ijms232214148","journal-title":"Int J Mol Sci"},{"key":"3713_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00213-005-0005-8","volume":"181","author":"WE Fantegrossi","year":"2005","unstructured":"Fantegrossi WE, Kiessel CL, De la Garza R 2nd, Woods JH. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl). 2005;181:529\u201336. https:\/\/doi.org\/10.1007\/s00213-005-0005-8","journal-title":"Psychopharmacology (Berl)"},{"key":"3713_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pbb.2007.06.007","volume":"88","author":"HL Yarosh","year":"2007","unstructured":"Yarosh HL, Katz EB, Coop A, Fantegrossi WE. MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacol Biochem Behav. 2007;88:18\u201327. https:\/\/doi.org\/10.1016\/j.pbb.2007.06.007","journal-title":"Pharmacol Biochem Behav"},{"key":"3713_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116532","volume":"349","author":"MJQ Chen","year":"2025","unstructured":"Chen MJQ, Chen-Li D, Chisamore N, Husain MI, Di Vincenzo JD, Mansur RB, et al. Non-hallucinogenic psychedelics for mood and anxiety disorders: a systematic review. Psychiatry Res. 2025;349:116532. https:\/\/doi.org\/10.1016\/j.psychres.2025.116532","journal-title":"Psychiatry Res"},{"key":"3713_CR24","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1021\/acschemneuro.8b00155","volume":"9","author":"LE Dunlap","year":"2018","unstructured":"Dunlap LE, Andrews AM, Olson DE. Dark classics in chemical neuroscience: 3,4-methylenedioxymethamphetamine. ACS Chem Neurosci. 2018;9:2408\u201327. https:\/\/doi.org\/10.1021\/acschemneuro.8b00155","journal-title":"ACS Chem Neurosci"},{"key":"3713_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.138","volume":"5","author":"MB Young","year":"2015","unstructured":"Young MB, Andero R, Ressler KJ, Howell LL. 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry. 2015;5:e1066. https:\/\/doi.org\/10.1038\/tp.2015.138","journal-title":"Transl Psychiatry"},{"key":"3713_CR26","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s00213-017-4684-8","volume":"234","author":"MB Young","year":"2017","unstructured":"Young MB, Norrholm SD, Khoury LM, Jovanovic T, Rauch SAM, Reiff CM, et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology (Berl). 2017;234:2883\u201395. https:\/\/doi.org\/10.1007\/s00213-017-4684-8","journal-title":"Psychopharmacology (Berl)"},{"key":"3713_CR27","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1016\/j.neuron.2025.06.012","volume":"113","author":"MK Jain","year":"2025","unstructured":"Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. The polypharmacology of psychedelics reveals multiple targets for potential therapeutics. Neuron. 2025;113:3129\u201342.e9. https:\/\/doi.org\/10.1016\/j.neuron.2025.06.012","journal-title":"Neuron"},{"key":"3713_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/164_2018_107","volume":"252","author":"CE Canal","year":"2018","unstructured":"Canal CE. Serotonergic psychedelics: experimental approaches for assessing mechanisms of action. Handb Exp Pharmacol. 2018;252:227\u201360. https:\/\/doi.org\/10.1007\/164_2018_107","journal-title":"Handb Exp Pharmacol"},{"key":"3713_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.tins.2020.11.008","volume":"44","author":"NK Savalia","year":"2021","unstructured":"Savalia NK, Shao L-X, Kwan AC. A dendrite-focused framework for understanding the actions of ketamine and psychedelics. Trends Neurosci. 2021;44:260\u201375. https:\/\/doi.org\/10.1016\/j.tins.2020.11.008","journal-title":"Trends Neurosci"},{"key":"3713_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","volume":"129","author":"M Wang","year":"2007","unstructured":"Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, et al. \u03b12A-Adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129:397\u2013410. https:\/\/doi.org\/10.1016\/j.cell.2007.03.015","journal-title":"Cell"},{"key":"3713_CR31","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1523\/JNEUROSCI.08-11-04287.1988","volume":"8","author":"AF Arnsten","year":"1988","unstructured":"Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. JNeuroSci. 1988;8:4287\u20134298. https:\/\/doi.org\/10.1523\/JNEUROSCI.08-11-04287.1988","journal-title":"JNeuroSci"},{"key":"3713_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0091-3057(91)90290-I","volume":"38","author":"NA Darmani","year":"1991","unstructured":"Darmani NA, Martin BR, Pandey U, Glennon RA. Inhibition of 5-HT2 receptor-mediated head-twitch response by cocaine via indirect stimulation of adrenergic \u03b12 and serotonergic 5-HT1A receptors. Pharmacol Biochem Behav. 1991;38:353\u20137. https:\/\/doi.org\/10.1016\/0091-3057(91)90290-I","journal-title":"Pharmacol Biochem Behav"},{"key":"3713_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/npp.2008.184","volume":"34","author":"HT Zhang","year":"2009","unstructured":"Zhang HT, Whisler LR, Huang Y, Xiang Y, O\u2019Donnell JM. Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior. Neuropsychopharmacology. 2009;34:1067\u201377. https:\/\/www.nature.com\/articles\/npp2008184","journal-title":"Neuropsychopharmacology"},{"key":"3713_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","volume":"62","author":"JA Giovannitti Jr","year":"2015","unstructured":"Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31\u20139. https:\/\/anesthesiaprogress.kglmeridian.com\/view\/journals\/anpr\/62\/1\/article-p31.xml","journal-title":"Anesth Prog"},{"key":"3713_CR35","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1523\/JNEUROSCI.21-13-04875.2001","volume":"21","author":"NL Schramm","year":"2001","unstructured":"Schramm NL, McDonald MP, Limbird LE. The alpha2A-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci. 2001;21:4875\u201382. https:\/\/doi.org\/10.1523\/JNEUROSCI.21-13-04875.2001","journal-title":"J Neurosci"},{"key":"3713_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl6554","volume":"10","author":"B Rein","year":"2024","unstructured":"Rein B, Raymond K, Boustani C, Tuy S, Zhang J, St Laurent R, et al. MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens. Sci Adv. 2024;10:eadl6554 https:\/\/www.science.org\/doi\/10.1126\/sciadv.adl6554","journal-title":"Sci Adv"},{"key":"3713_CR37","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1038\/s41380-025-03128-4","volume":"30","author":"MB Pomrenze","year":"2025","unstructured":"Pomrenze MB, Vaillancourt S, Salgado JS, Raymond KB, Llorach P, Sacai H, et al. 5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA. Mol Psychiatry. 2025;30:5405\u20135416. https:\/\/doi.org\/10.1038\/s41380-025-03128-4","journal-title":"Mol Psychiatry"},{"key":"3713_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00213-002-1269-x","volume":"165","author":"ME Page","year":"2003","unstructured":"Page ME, Brown K, Lucki I. Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action. Psychopharmacology (Berl). 2003;165:194\u2013201. https:\/\/doi.org\/10.1007\/s00213-002-1269-x","journal-title":"Psychopharmacology (Berl)"},{"key":"3713_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1423-0127-16-72","volume":"16","author":"YP Liu","year":"2009","unstructured":"Liu YP, Lin YL, Chuang CH, Lin JY, Lai CC, Chen IJ. Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task. J Biomed Sci. 2009;16:72. https:\/\/doi.org\/10.1186\/1423-0127-16-72","journal-title":"J Biomed Sci"},{"key":"3713_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1527-3458.2005.tb00047.x","volume":"11","author":"A Pertovaara","year":"2005","unstructured":"Pertovaara A, Haapalinna A, Sirvi\u00f6 J, Virtanen R. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev. 2005;11:273\u201388. https:\/\/doi.org\/10.1111\/j.1527-3458.2005.tb00047.x","journal-title":"CNS Drug Rev"},{"key":"3713_CR41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ALN.0b013e31817c02fc","volume":"109","author":"J H\u00f6cker","year":"2008","unstructured":"H\u00f6cker J, Paris A, Scholz J, Tonner PH, Nielsen M, Bein B. Differential effects of \u03b12-adrenoceptors in the modulation of the thermoregulatory response in mice induced by meperidine. Anesthesiology. 2008;109:95\u2013100. https:\/\/journals.lww.com\/anesthesiology\/fulltext\/2008\/07000\/differential_effects_of__2_adrenoceptors_in_the.15.aspx","journal-title":"Anesthesiology"},{"key":"3713_CR42","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/s41386-020-0641-z","volume":"45","author":"RE Perez","year":"2020","unstructured":"Perez RE, Basu A, Nabit BP, Harris NA, Folkes OM, Patel S, et al. \u03b12A-adrenergic heteroreceptors are required for stress-induced reinstatement of cocaine conditioned place preference. Neuropsychopharmacology. 2020;45:1473\u201381. https:\/\/www.nature.com\/articles\/s41386-020-0641-z","journal-title":"Neuropsychopharmacology"},{"key":"3713_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1744-9081-2-41","volume":"2","author":"T Sagvolden","year":"2006","unstructured":"Sagvolden T. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of ADHD. Behav Brain Funct. 2006;2:41. https:\/\/doi.org\/10.1186\/1744-9081-2-41","journal-title":"Behav Brain Funct"},{"key":"3713_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49913-4","volume":"9","author":"M de la Fuente Revenga","year":"2019","unstructured":"de la Fuente Revenga M, Shin JM, Vohra HZ, Hideshima KS, Schneck M, Poklis JL, et al. Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo. Sci Rep. 2019;9:14247 https:\/\/doi.org\/10.1038\/s41598-019-49913-4","journal-title":"Sci Rep"},{"key":"3713_CR45","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41386-023-01572-w","volume":"48","author":"SJ Jefferson","year":"2023","unstructured":"Jefferson SJ, Gregg I, Dibbs M, Liao C, Wu H, Davoudian PA, et al. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology. 2023;48:1257\u201366. https:\/\/doi.org\/10.1038\/s41386-023-01572-w","journal-title":"Neuropsychopharmacology"},{"key":"3713_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci USA. 2021;118:e2022489118. https:\/\/doi.org\/10.1073\/pnas.2022489118","journal-title":"Proc Natl Acad Sci USA"},{"key":"3713_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00401509","volume":"11","author":"SJ Corne","year":"1967","unstructured":"Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967;11:65\u201378. https:\/\/doi.org\/10.1007\/BF00401509","journal-title":"Psychopharmacologia"},{"key":"3713_CR48","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00213-013-3006-z","volume":"227","author":"AL Halberstadt","year":"2013","unstructured":"Halberstadt AL, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl). 2013;227:727\u201339. https:\/\/doi.org\/10.1007\/s00213-013-3006-z","journal-title":"Psychopharmacology (Berl)"},{"key":"3713_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-021-00686-5","volume":"23","author":"Y Sun","year":"2022","unstructured":"Sun Y, Chebolu S, Henry D, Lankireddy S, Darmani NA. An ontogenic study of receptor mechanisms by which acute administration of low-doses of methamphetamine suppresses DOI-induced 5-HT2A-receptor mediated head-twitch response in mice. BMC Neurosci. 2022;23:2. https:\/\/doi.org\/10.1186\/s12868-021-00686-5","journal-title":"BMC Neurosci"},{"key":"3713_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.775070","volume":"12","author":"RA Flores","year":"2021","unstructured":"Flores RA, Dos-Santos RC, Steinbach R, Rodrigues-Santos I, de Jesus AA, Antunes-Rodrigues J, et al. \u03b1-1 Adrenoceptor activation in the dorsal raphe nucleus decreases food intake in fasted rats. Front Physiol. 2021;12:775070. https:\/\/doi.org\/10.3389\/fphys.2021.775070","journal-title":"Front Physiol"},{"key":"3713_CR51","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"key":"3713_CR52","doi-asserted-by":"publisher","unstructured":"Mitchell JM, Ot\u2019alora G M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02565-4","DOI":"10.1038\/s41591-023-02565-4"},{"key":"3713_CR53","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans. Clin Pharmacol Ther. 2011;90:246\u2013255. https:\/\/doi.org\/10.1038\/clpt.2011.78","journal-title":"Clin Pharmacol Ther"},{"key":"3713_CR54","doi-asserted-by":"publisher","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Kr\u00e4henb\u00fchl S, et al. Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 2012;7:e36476 https:\/\/doi.org\/10.1371\/journal.pone.0036476","journal-title":"PLoS One"},{"key":"3713_CR55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22:513\u2013521. https:\/\/doi.org\/10.1016\/S0893-133X(99)00148-7","journal-title":"Neuropsychopharmacology"},{"key":"3713_CR56","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/026988110001400313","volume":"14","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (\u2018Ecstasy\u2019) in healthy volunteers. J Psychopharmacol. 2000;14:269\u201374. https:\/\/doi.org\/10.1177\/026988110001400313","journal-title":"J Psychopharmacol"},{"key":"3713_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112342","volume":"379","author":"MD Wei","year":"2020","unstructured":"Wei MD, Wang YH, Lu K, Lv BJ, Wang Y, Chen WY. Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice. Behav Brain Res. 2020;379:112342. https:\/\/doi.org\/10.1016\/j.bbr.2019.112342","journal-title":"Behav Brain Res"},{"key":"3713_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1546460","volume":"19","author":"M Boese","year":"2025","unstructured":"Boese M, Berman R, Radford K, Johnson LR, Choi K. Effects of ketamine on fear memory extinction: a review of preclinical literature. Front Neurosci. 2025;19:1546460. https:\/\/doi.org\/10.3389\/fnins.2025.1546460","journal-title":"Front Neurosci"},{"key":"3713_CR59","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.physbeh.2006.01.037","volume":"87","author":"JA Beeler","year":"2006","unstructured":"Beeler JA, Prendergast B, Zhuang X. Low amplitude entrainment of mice and the impact of circadian phase on behavior tests. Physiol Behav. 2006;87:870\u2013880. https:\/\/doi.org\/10.1016\/j.physbeh.2006.01.037","journal-title":"Physiol Behav"},{"key":"3713_CR60","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/brainsci11040522","volume":"11","author":"RM Sar\u00e9","year":"2021","unstructured":"Sar\u00e9 RM, Lemons A, Smith CB. Behavior testing in rodents: highlighting potential confounds affecting variability and reproducibility. Brain Sci. 2021;11:522. https:\/\/doi.org\/10.3390\/brainsci11040522","journal-title":"Brain Sci"},{"key":"3713_CR61","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/neuro.01.029.2008","volume":"2","author":"M Yang","year":"2008","unstructured":"Yang M, Weber MD, Crawley JN. Light phase testing of social behaviors: not a problem. Front Neurosci. 2008;2:186\u2013191. https:\/\/doi.org\/10.3389\/neuro.01.029.2008","journal-title":"Front Neurosci"},{"key":"3713_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/biology9070180","volume":"9","author":"RG Foster","year":"2020","unstructured":"Foster RG, Hughes S, Peirson SN. Circadian Photoentrainment in Mice and Humans. Biology (Basel). 2020;9:180. https:\/\/doi.org\/10.3390\/biology9070180","journal-title":"Biology (Basel)"},{"key":"3713_CR63","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/dta.1333","volume":"4","author":"CE Canal","year":"2012","unstructured":"Canal CE, Morgan D. Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal. 2012;4:556\u201376. https:\/\/doi.org\/10.1002\/dta.1333","journal-title":"Drug Test Anal"},{"key":"3713_CR64","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/sj.bjp.0707473","volume":"152","author":"T Montgomery","year":"2007","unstructured":"Montgomery T, Buon C, Eibauer S, Guiry PJ, Keenan AK, McBean GJ. Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines. Br J Pharmacol. 2007;152:1121\u201330. https:\/\/doi.org\/10.1038\/sj.bjp.0707473","journal-title":"Br J Pharmacol"},{"key":"3713_CR65","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","volume":"168","author":"LD Simmler","year":"2013","unstructured":"Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458\u201370. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02145.x","journal-title":"Br J Pharmacol"},{"key":"3713_CR66","doi-asserted-by":"publisher","unstructured":"Maltby CJ, Klein AK, Paschen E, Pinto J, Dvorak D, Hedde JR, et al. An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice. J Psychopharmacol. 2026:2698811251395386. https:\/\/doi.org\/10.1177\/02698811251395386","DOI":"10.1177\/02698811251395386"},{"key":"3713_CR67","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1021\/acsptsci.2c00222","volume":"6","author":"GC Glatfelter","year":"2023","unstructured":"Glatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, et al. Receptor binding profiles for tryptamine psychedelics and effects of 4-Propionoxy-N,N-dimethyltryptamine in mice. ACS Pharmacol Transl Sci. 2023;6:567\u2013577. https:\/\/doi.org\/10.1021\/acsptsci.2c00222","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3713_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113612","volume":"154","author":"I Erkizia-Santamar\u00eda","year":"2022","unstructured":"Erkizia-Santamar\u00eda I, Alles-Pascual R, Horrillo I, Meana JJ, Ortega JE. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomed Pharmacother. 2022;154:113612. https:\/\/doi.org\/10.1016\/j.biopha.2022.113612","journal-title":"Biomed Pharmacother"},{"key":"3713_CR69","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00213-006-0531-z","volume":"189","author":"QD Walker","year":"2007","unstructured":"Walker QD, Williams CN, Jotwani RP, Waller ST, Francis R, Kuhn CM. Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Psychopharmacology (Berl). 2007;189:435\u201345. https:\/\/doi.org\/10.1007\/s00213-006-0531-z","journal-title":"Psychopharmacology (Berl)"},{"key":"3713_CR70","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pbb.2016.08.004","volume":"152","author":"MF Lazenka","year":"2017","unstructured":"Lazenka MF, Suyama JA, Bauer CT, Banks ML, Negus SS. Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol Biochem Behav. 2017;152:52\u201360. https:\/\/doi.org\/10.1016\/j.pbb.2016.08.004","journal-title":"Pharmacol Biochem Behav"},{"key":"3713_CR71","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002130000648","volume":"154","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154:161\u20138. https:\/\/doi.org\/10.1007\/s002130000648","journal-title":"Psychopharmacology (Berl)"},{"key":"3713_CR72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neubiorev.2006.09.009","volume":"31","author":"K Allott","year":"2007","unstructured":"Allott K, Redman J. Are there sex differences associated with the effects of ecstasy\/3,4-methylenedioxymethamphetamine (MDMA)? Neurosci Biobehav Rev. 2007;31:327\u201347. https:\/\/doi.org\/10.1016\/j.neubiorev.2006.09.009","journal-title":"Neurosci Biobehav Rev"},{"key":"3713_CR73","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.brainres.2015.11.021","volume":"1641","author":"DA Bangasser","year":"2016","unstructured":"Bangasser DA, Wiersielis KR, Khantsis S. Sex differences in the locus coeruleus-norepinephrine system and its regulation by stress. Brain Res. 2016;1641:177\u201388. https:\/\/doi.org\/10.1016\/j.brainres.2015.11.021","journal-title":"Brain Res"},{"key":"3713_CR74","doi-asserted-by":"publisher","first-page":"136836","DOI":"10.1016\/j.neulet.2022.136836","volume":"788","author":"AM Jaster","year":"2022","unstructured":"Jaster AM, Younkin J, Cuddy T, de la Fuente Revenga M, Poklis JL, Dozmorov MG, et al. Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL\/6J mice. Neurosci Lett. 2022;788:136836. https:\/\/doi.org\/10.1016\/j.neulet.2022.136836","journal-title":"Neurosci Lett"},{"key":"3713_CR75","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1021\/acschemneuro.4c00279","volume":"15","author":"SC Woodburn","year":"2024","unstructured":"Woodburn SC, Levitt CM, Koester AM, Kwan AC. Psilocybin facilitates fear extinction: importance of dose, context, and serotonin receptors. ACS Chem Neurosci. 2024;15:3034\u20133043. https:\/\/doi.org\/10.1021\/acschemneuro.4c00279","journal-title":"ACS Chem Neurosci"},{"key":"3713_CR76","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae083","volume":"165","author":"S Shadani","year":"2024","unstructured":"Shadani S, Conn K, Andrews ZB, Foldi CJ. Potential differences in psychedelic actions based on biological sex. Endocrinology. 2024;165:bqae083. https:\/\/doi.org\/10.1210\/endocr\/bqae083","journal-title":"Endocrinology"},{"key":"3713_CR77","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0022-3565(24)36840-5","volume":"282","author":"DL Willins","year":"1997","unstructured":"Willins DL, Meltzer HY. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther. 1997;282:699\u2013706. https:\/\/pubmed.ncbi.nlm.nih.gov\/9262333\/","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03713-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03713-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03713-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:57:57Z","timestamp":1792011477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03713-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03713-1","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were performed in accordance with the protocols approved by the Yale Institutional Animal Care and Use Committee (Approval No. 20381). Written informed consent was not required, as no human participant was involved in this study. All methods were performed in accordance with the relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Research funding from Freedom Biosciences and Transend Therapeutics (APK, CP). A patent application relevant to this manuscript has been filed by APK, ALY, AFR, JHK, CP. ACK has been a scientific advisor or consultant for Boehringer Ingelheim, Eli Lilly, Empyrean Neuroscience, Freedom Biosciences, Otsuka, and Xylo Bio. ACK has received research support from Intra-Cellular Therapies. BK serves as the Chief Scientific Advisor for Transcend Therapeutics, and he\u2019s a co-founder and serves as a consultant for Transcend Therapeutics. He served as a consultant in the past year for Ceruvia Lifesciences and Lobe Sciences. JK (consultations less than $5000\/yr) Aptinyx, Inc., BioXcel, Biogen, Idec, MA, Bionomics, Limited (Australia), Boehringer Ingelheim International, Cerevel Pharmaceuticals, Epiodyne, Inc., Esai, Inc., Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., PsychoGenics, Inc., Sunovion Pharmaceuticals, Inc., Takeda Pharmaceuticals (Stock\/Options) Biohaven Pharmaceuticals, Cartego Therapeutics, Damona Pharmaceuticals, Delix Therapeutics, Inc., EpiVario, Inc., Freedom Biosciences, Neumora Therapeutics, Inc., Response Pharmaceuticals, Rest Therapeutics, Spring Health, Inc, Tempero Bio, Inc, Terran Biosciences, Tetricus Inc (non-monetary support, i.e., provision of drug) Cerevel Pharmaceuticals, Novartis. Dr. Krystal stands to benefit from patents held by Yale University that were licensed to Janssen Pharmaceuticals (ketamine), Biohaven Pharmaceuticals (riluzole), Freedom Biosciences (NMDA-R antagonist plus MTORC inhibitor), and Spring Health (precision medicine strategy). PRC is Co-founder and Board Member of Tetricus Labs, a precision-psychiatry company who did not fund this work. CP consults for Biohaven Pharmaceuticals, Ceruvia Lifesciences, Transcend Therapeutics, Freedom Biosciences, Nobilis Therapeutics, UCB Biopharma, and F-Prime Capital Partners and receives research funding from Biohaven, Transcend, and Freedom. He has filed patents for psychedelics in the treatment of obsessive-compulsive disorder and the identification of autoantibodies in neuropsychiatric disease, both unrelated to the current work. He owns equity in Alco Therapeutics for drug development unrelated to this work. JWS is a full-time employee with equity in Transcend Therapeutics.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}